Jonathan Bridges, MD
Internal Medicine · Newington, NHNPI 1083744510
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (46.9%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Medtronic at 38.6% of the total. Reporting peaked in 2024 at $5,737 and has fallen 54.1% since, to $2,631 in 2025. Among internal medicine clinicians in NH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 150 payments — averaging $106.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$6K
- Edwards Lifesciences$4K
- Boston Scientific$3K
- Abbott$790
- Shockwave Medical, Inc$389
- Johnson & Johnson$270
- plus $2K from 19 others
What the payments were for
- Consulting fees$1,2908%
- Travel & lodging$7,51647%
- Food & beverage$7,18445%
- Education$180%
- Entertainment$240%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 36 | $6,192 |
| Edwards Lifesciences | 20 | $3,612 |
| Boston Scientific | 17 | $3,011 |
| Abbott | 14 | $790 |
| Shockwave Medical, Inc | 7 | $389 |
| Johnson & Johnson | 11 | $270 |
| E.r. Squibb & Sons, L.L.C. | 15 | $245 |
| Bard Peripheral Vascular, Inc. | 1 | $214 |
| Stryker | 1 | $176 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $139 |
| Novo Nordisk | 1 | $110 |
| Inari Medical, Inc. | 3 | $110 |
| Novartis | 1 | $93 |
| Livanova USA, Inc. | 1 | $93 |
| AstraZeneca | 1 | $88 |
| Sanofi-aventis U.S. LLC | 1 | $86 |
| Cardiovascular Systems Inc. | 1 | $84 |
| Actelion Pharmaceuticals US, Inc. | 1 | $80 |
| Abiomed | 2 | $54 |
| Boehringer Ingelheim | 2 | $48 |
| Pfizer | 3 | $43 |
| Regeneron Healthcare Solutions, Inc. | 2 | $35 |
| Opsens Inc. | 1 | $24 |
| EKOS Corporation | 1 | $23 |
| Asahi Intecc USA, Inc. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ADVISA DR MRI SURESCAN$4,680
- SAPIEN 3 Ultra RESILIA$1,741
- Edwards SAPIEN 3 Transcatheter Heart Valve$1,281
- COREVALVE EVOLUT R$307
- MitraClip$194
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$193
- FLOWTRIEVER CATHETER, S$176
- CT THROMBECTOMY SYSTEM KIT$176
- Optis Coronary Imaging System$147
- EKOSONIC$108
- Emboshield NAV6 system$103
- XARELTO$103
How this compares
$16,032 in reported general payments places this provider in the 95th percentile of 504 internal medicine providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 140 | $189,938 |
| XareltoRivaroxaban | 54 | $75,537 |
| EntrestoSacubitril/Valsartan | 19 | $26,085 |
| Repatha SureclickEvolocumab | 16 | $15,130 |
| Prasugrel Hcl | 42 | $4,350 |
| Atorvastatin Calcium | 310 | $3,418 |
| Ranolazine ErRanolazine | 23 | $2,945 |
| Metoprolol Succinate | 157 | $2,151 |
| Metoprolol Tartrate | 194 | $1,639 |
| Amlodipine Besylate | 171 | $1,563 |
| Rosuvastatin Calcium | 82 | $1,447 |
| ClopidogrelClopidogrel Bisulfate | 148 | $1,377 |
| Lisinopril | 175 | $1,267 |
| Carvedilol | 49 | $637 |
| Diltiazem Hcl | 13 | $567 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $43 | $189,938140 claims |
| Johnson & JohnsonXarelto | $270 | $75,53754 claims |
| NovartisEntresto | $93 | $26,08519 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 504 internal medicine providers in New Hampshire.
Other internal medicine in Newington
- Mark HenschkeNewington$114K
- Donald RainoneLondonderry$1.9M
- Brian HyettPortsmouth$185K
- Deborah TepperLebanon$133K
- William MonacoLebanon$97K
- Kevin PhoNashua$40K
- Mary McGowanLebanon$26K
- Magued Rizkalla HannaPortsmouth$26K
- Daniel FeldmanLebanon$17K
- Amir Soheil TolebeyanLebanon$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.